COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. David Filpula

Dr. David Filpula

Scientific Review Officer


Division of Basic and Integrative Biological Sciences DBIB
Bioengineering Sciences and Technologies BST
Study Section:
High Throughput Screening BST-F (55)

Dr. David Filpula received his Ph.D. in biochemistry at the University of Minnesota and completed postdoctoral training in protein chemistry and molecular genetics at Stanford University and the University of California, San Diego. Subsequently, he served for nearly three decades as a research director at biotechnology companies in New Jersey and Maryland. David led diverse teams of research scientists at Enzon Pharmaceuticals and Genex Corporation and was engaged in programs that successfully led to several marketed biopharmaceuticals, commercial life science research products, and industrial biochemical technologies. Dr. Filpula also served as Director of Research for SCA Ventures and joined the Steering Committee for an international alliance of biotechnology companies focused on antibody engineering. David has numerous patents, publications, and platform talks in the areas of protein engineering and drug delivery and was Principal Investigator on several extramural grants funded through the Small Business Innovation Research program prior to joining CSR as a Scientific Review Officer in 2011, serving first in Interdisciplinary Molecular Sciences and Training and subsequently in Bioengineering Sciences and Technologies.